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Morbidly obese patients exhibit impaired secretion of gut hormones that may 
contribute to the development of obesity.  After bariatric surgery there is a dramatic 
increase in gut hormone release.  In this study, gastric and duodenal tissues were 
endoscopically collected from lean, and morbidly obese subjects before and 3 
months after laparoscopic sleeve gastrectomy (LSG).  Tissue morphology, 
abundance of chromogranin A, gut hormones, α-defensin, mucin 2, Na+/glucose co-
transporter 1 (SGLT1) and transcription factors, Hes1, HATH1, NeuroD1, and Ngn3, 
were determined. 
In obese patients, the total number of enteroendocrine cells (EEC) and EECs 
containing gut hormones were significantly reduced in the stomach and duodenum, 
compared to lean, and returned to normality post-LSG.  No changes in villus 
height/crypt depth were observed.  A significant increase in mucin 2 and SGLT1 
expression was detected in the obese duodenum.  Expression levels of transcription 
factors required for differentiation of absorptive and secretory cell lineages were 
altered. 
We propose that in obesity, there is deregulation in differentiation of intestinal 
epithelial cell lineages that may influence the levels of released gut hormones.  Post-
LSG cellular differentiation profile is restored.  An understanding of molecular 
mechanisms controlling epithelial cell differentiation in the obese intestine assists in 
the development of non-invasive therapeutic strategies. 
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Introduction 
Obesity and its associated conditions, such as type-2 diabetes and cardiovascular 
disease, are major health threats worldwide.  This condition is partly caused by 
inability to sense satiation after meals.  The intestinal epithelium is a site of satiation 
signal generation, where specialized enteroendocrine (sensor) cells (EECs) respond 
to nutrients by releasing hormones that control energy homeostasis, food intake and 
insulin secretion1,2. 
EECs, dispersed among the cells lining the intestinal epithelium, represent 
approximately 1% of the entire gut epithelial cell population, but together they 
constitute the largest endocrine organ of the body.  Traditionally it has been accepted 
that the discrete cell types that make up the EEC family have a distinct hormonal 
profile and localisation along the length of the gut3.  However, recent investigations 
have shown that the one hormone, one cell dogma may not always be correct, and 
that there are more complex patterns of gut hormone co-localisation in EECs4.  In 
general, cholecystokinin (CCK) is released by I-cells predominantly located in the 
proximal small intestine, whereas peptide YY (PYY) and glucagon-like peptide 1 and 
2 (GLP-1, GLP-2) are secreted predominantly by L-cells residing mostly in the distal 
gut5-7.  However, L-cells have also been identified in the duodenum with higher 
numbers observed in jejunum and ileum8.  CCK, GLP-1and PYY regulate gastric 
emptying and food intake, with GLP-1 also functioning as an incretin hormone, 
stimulating insulin secretion9,10.  Ghrelin is released by enteroendocrine X/A cells of 
the stomach, and by open-type EECS of the duodenum, acting as an orexigenic 
hormone, stimulating appetite and food intake11-13. 
Absorptive enterocytes, mucus-producing goblet cells and Paneth cells are the other 
epithelial cells lining the intestine.  All four cell types differentiate from common 
pluripotent stem cells located near the base of the crypt compartment of the intestine. 
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Cell labelling kinetics has indicated that absorptive enterocytes, goblet and 
enteroendocrine cells migrate up the crypt-villus axis turning over every 3-4 days, 
whereas Paneth cells migrate downwards to the crypt base being renewed with a 
much slower turnover of approximately 21 days14. 
Absorptive enterocytes are the most abundant cell type in the small intestine (~90%), 
and they participate mainly in transcellular transport of nutrients15.  Goblet cells are 
the most copious secretory lineage of the intestinal epithelia, comprising up to 10% of 
small intestinal epithelial cells16.  They produce and secrete mucus to provide 
epithelial cells a protective shield against noxious luminal contents.  Paneth cells 
produce antimicrobial peptides such as defensins that are secreted into the lumen of 
the intestine17. 
 
The Notch pathway plays a critical role in intestinal epithelial cell fate by regulating 
the choice of absorptive versus secretory lineages.  Notch induces stem cells to 
express Hes1, a transcription factor proposed to be one of the primary mediators of 
intestinal Notch signals.  Hes1 represses HATH1, a specific secretory lineage 
transcription factor and thus driving cells to become absorptive enterocytes16.  In 
Hes1 deficient mice, HATH1 expression is increased leading to fewer absorptive 
enterocytes and increased goblet and endocrine cells18. 
Differentiation of EECs is controlled by the sequential expression of, HATH1 and two 
other basic helix-loop-helix transcription factors, Neurogenin 3 (Ngn3) and NeuroD1.  
HATH 1 is required for specification and segregation of the intestinal secretory 
lineage (Paneth, goblet and enteroendocrine cells) from the absorptive enterocyte 
lineage.  Ngn3 expression represents the earliest stage of enteroendocrine 
differentiation and in its absence enteroendocrine cells fail to develop19.  Subsequent 
expression of NeuroD1 appears to represent a later stage of differentiation for 
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maturing EECs.  Enteroendocrine cell fate is inhibited by the Notch signalling 
pathway, which appears to inhibit both HATH1 and Ngn319.  Recent studies 
demonstrating increased numbers of EECs, reduced number of goblet cells, and 
absence of Paneth cells in Gfi-1 transcription factor-null mice propose additional 
secretory precursors segregating from HATH-1 dependent cells20. 
 
Morbidly obese patients exhibit impaired secretion of gut hormones CCK, GLP-1 and 
PYY that may contribute to the development of obesity.  Certain bariatric procedures 
such as Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy 
(LSG) cause weight loss and induce changes in both gut hormone, and insulin 
secretion together with improvements in glucose metabolism10,21,22. 
LSG is becoming a widely used method in the treatment of morbid obesity.  In 2011 
almost 30% of all bariatric interventions performed worldwide were LSGs23.  It has 
proved to be effective in terms of sustainable weight loss and amelioration of co- 
morbidities such as arterial hypertension and glucose intolerance, amongst 
others24,25.  This is probably achieved by a combination of reduction in stomach 
volume capacity, acceleration of food passage and hormonal changes21,25-27.  In 
obese individuals, gut hormone secretion is impaired with lower postprandial levels of 
circulating CCK, GLP-1 and PYY28-30.  The concentrations of fasting ghrelin in the 
majority of obese are lower than normal-weight individuals, and they do not show a 
calorie-dependent suppression in postprandial circulating ghrelin as observed in 
normal weight volunteers31.  Meal stimulation before and after bariatric surgery 
reveals dramatic increases in circulatory levels of gut hormones such as GLP-1, PYY 
and CCK as early as one week after intervention, well before weight loss occurs10.  
The effect of increased secretion of GLP-1 and PYY after bariatric surgery is not well 
understood, but the mechanism underlying this over-secretion in RYGB has been 
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proposed to be due to accelerated travel of nutrients to the distal gut32; this proposed 
mechanism however does not entirely explain increased gut hormone secretion in 
LSG. 
We hypothesised that there is a decrease in the number of EECs in obese subjects 
and that this decrease contributes to the observed decline in postprandial gut 
hormone levels.  Furthermore, we aimed to understand the causal processes of 
increased gut hormone release after LSG. 
In this study, we first confirmed that there is a significant increase in postprandial 
GLP-1, PYY and CCK release in a cohort of morbidly obese subjects 3 months post 
LSG compared to that in the same individuals, pre LSG.  A concurrent decrease in 
circulating ghrelin levels was also seen post LSG.  Subsequently, we demonstrated 
in a separate, but comparable, cohort of morbidly obese subjects, from whom we 
could secure consent for obtaining stomach and duodenal biopsies, that there is a 
significant decrease in the total number of EECs in the stomach and the duodenum, 
compared to lean subjects.  EEC numbers were restored post-operatively.  There 
were no changes in villus height and crypt-depth between the two groups.  
Furthermore, in obese individuals, there was a significant increase in the expression 
levels of the intestinal glucose transporter, SGLT1 (-a marker of absorptive 
enterocytes), and the major component of intestinal mucus, mucin 2 (an indicator of 
goblet cells), indicating that there is deregulation of processes controlling cellular 
differentiation.  Accordingly, we demonstrated that protein abundance of transcription 
factors required for differentiation of intestinal absorptive and secretory cell lineages 
was also altered; these were returned to normality after LSG. 
Understanding mechanisms underlying deregulation of intestinal epithelial cell 
differentiation in obesity may facilitate identifying potential targets for preventing or 
treating obesity and associated conditions.  
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Results 
Circulating gut hormone levels in a cohort of morbidly obese subjects (Group 
1) before and after LSG.  Analysis of pre- and postoperative data from group 1, 
consisting of 14 morbidly obese subjects, demonstrated that there was a marked 
reduction in BMI (p < 0.001), HOMA index (Homeostasis model assessment: [fasting 
insulin x fasting glucose]/22.5; (p = 0.02), fasting insulin (p = 0.04) and fasting 
glucose (p = 0.008), at 3 months post-LSG (Table 1, Figure S1).  A significant 
increase in postprandial GLP-1, PYY and CCK-responses were shown with 2.9- (p < 
0.001), 5.7- (p < 0.001) and 1.7-fold (p < 0.01) increases in maximum plasma 
concentrations of CCK, GLP-1 and PYY, respectively, in 3 month postoperative 
patients (Table 1, Figure S1).  Preoperatively, area under the curve values for each 
hormone were significantly lower (Table 1, Figure S1).  A concurrent 1.7-fold (p < 
0.001) decrease in circulating ghrelin levels was also seen 3 months postoperative 
(Table 1, Figure S1).  Our investigations indicated that age did not affect the 
hormone responses. 
 
Determination of tissue expression of gut hormones in the stomach and 
duodenum of morbidly obese subjects (Group 2).  Twenty seven non-diabetic 
morbidly obese subjects, who consented to provide stomach and duodenal biopsies 
pre- and post LSG, were used in this study.  There were 6 drop-outs (5 patients did 
not want to come back after surgery, one patient had an incidental finding of antrum 
carcinoma and had to be excluded).  Of the morbidly obese patients, 21.1% (7/33); 
were positive for Helicobacter pylori preoperatively.  After surgery there was a 
marked reduction in BMI from 47.2 ± 1.7 kg/m2 (range: 35.6-75.7) to 39.3 ± 1.4 kg/m2 
(range: 27.1-53.2).  The control group consisted of 24 healthy lean subjects (Table 
2). 
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Assessment of chromogranin A- and ghrelin- containing EECs in the stomach.  Using 
immunohistochemistry, we showed that there was a 2.2- (p < 0.001) and 2.7-fold (p < 
0.001) decline in the total number of chromogranin A (ChA)- containing EECs in the 
lesser and greater curvature of the stomach, respectively, in obese compared to lean 
individuals.  In the same obese individuals post-operatively there was a 1.6-fold (p < 
0.05) increase in the number of these cells in the lesser curvature compared to pre-
LSG (Figures S2; Table S1).  Tissues from the greater curvature were no longer 
available after surgery to be compared.  Using an average cell count of 500, we 
observed a 2.5- (p < 0.001) and 2.8-fold (p < 0.001) decrease in EECs containing 
ghrelin in the lesser and greater curvature respectively, in the obese stomach 
compared to lean.  The number of ghrelin-containing cells was increased 1.5-fold (p 
< 0.05) in lower curvature of post-operative vs. preoperative obese subjects, however 
this was still 1.5-fold (p < 0.05) lower than lean controls.  We showed, that the greater 
and lesser curvature of the stomach do not contain EECs possessing CCK, GLP-1, 
GLP-2 or PYY.  The total number of cells counted that contain ChA and ghrelin is 
given in Table S1. 
 
Assessment of the number of chromogranin A and gut hormone containing EECs in 
the duodenum.  By immunohistochemistry we demonstrated that there was a 1.7-fold 
(p < 0.001) decrease in the total number of EECs in the duodenum of obese patients 
compared to lean controls (Figure 1A, Table S1).  Using qPCR, a 1.8-fold (p < 0.05) 
reduction in ChA mRNA expression was also observed in obese duodenal biopsies, 
compared to lean controls (Figure 2).  The population of EECs in the duodenum, 
determined by immunohistochemistry, increased 1.6-fold (p < 0.001) 3-month 
postoperatively, reaching 96% of the total number of EECs observed in lean controls 
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(Figure 1A).  There was 1.8-fold (p < 0.01) decrease in the number of CCK-
containing cells in the duodenum of obese compared to lean controls.  However, 3 
months post-surgery, the number of CCK-expressing EECs in these individuals 
increased 1.5-fold (p < 0.05) (Figure 1B).  A 2.1-fold (p < 0.001) decline in ghrelin-
expressing EECs in the duodenum of obese patients, in comparison to lean, was fully 
restored postoperatively (p < 0.001) (Figure 1C).  We report here for the first time that 
human duodenum contains EECs that express PYY, albeit in low numbers.  In an 
average of 100 cells counted, PYY- containing EECs were 2.8-fold (p < 0.001) lower 
in obese compared to lean controls but displayed a 1.5-fold (p < 0.05) increase post-
operatively (Figure 3A); however the number of PYY-positive cells in the duodenum 
post-LSG was still 1.8-fold (p < 0.05) lower than lean controls.  Furthermore, we 
show some EECs in human duodenum express GLP-1 and GLP-2, although as 
expected, the number of GLP-1 and GLP-2 expressing EECs are significantly lower 
than those expressing CCK or PYY.  Duodenal EECs expressing GLP-1 and GLP-2 
show a 2.5- (p < 0.001) and 2.9-fold (p < 0.001) reduction, respectively, in obese 
patients compared to lean controls.  Post-operatively the number of GLP-1 and GLP-
2 containing EECs increased 2.1- (p < 0.001) and 2.6-fold (p < 0.001), respectively, 
compared to pre-operative levels (Figure 3B, C).  The findings that that the number of 
duodenal PYY- containing cells in the post-operative  obese group was lower than in 
lean controls, contrasts with the number of GLP- positive cells in two groups.  This 
may indicate that in human duodenum PYY and GLP-1/2 may be expressed in 
distinct and separate L-cells.  The total number of cells counted that contain ChA and 
each respective gut hormone are given in the supplementary information (Table S1). 
 
Morphometric analysis of duodenal tissue.  By morphometric analysis we 
observed that there were no differences in villus height/crypt depth in the duodenal 
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tissues of lean, obese and obese individuals after LSG, suggesting that the decline in 
EEC number is not due to any changes in intestinal surface area (Figure S3).  A total 
of ~250 images each for lean, obese pre-op and obese post-op were used. 
 
Expression of intestinal epithelial cell markers in the duodenum.  In order to 
determine whether the alterations in the number of EECs in the intestine of obese 
subjects, may be observed with other intestinal epithelial cells, we determined the 
expression levels of defensin 5, a marker of Paneth cells17 and mucin 2 (MUC2), an 
indicator of goblet cells33 (using qPCR and immunohistochemistry) in duodenal 
tissues of lean and obese individuals.  The protein abundance of Na+/glucose co-
transporter 1 (SGLT1), a classical marker of absorptive enterocytes, was also 
assessed (by western blotting).  No significant difference in the expression of 
defensin 5 mRNA was detected in the intestine of obese compared to lean (Figure 
4A), but a moderate 1.3-fold (p <0.01) decline in cells expressing defensin 5 protein, 
measured by immunohistochemistry, was observed in obese compared to lean 
controls (Figure 4B), and in post-LSG.  A marked1.9-fold (p < 0.01) increase in 
MUC2 mRNA expression (Figure 4A) and a correlated 1.8-fold increase in MUC2 
protein abundance (p < 0.001) (Figure 4B) were seen in the duodenum of obese 
compared to lean controls; this increase was reversed 4-fold (p < 0.001), post-
operatively (Figure 4B).  The expression of SGLT1 protein was 1.5-fold (p = 0.0114) 
higher in the intestine of obese compared to lean individuals; and was reversed with 
a 1.7-fold (p = 0.0262) reduction, post-operatively (Figure 5A). 
 
Protein abundance of transcription factors.  The abundance of the transcription 
factors NeuroD1, Ngn3, HATH1 and Hes1 proteins was assessed in duodenal 
biopsies from lean, obese and obese post-LSG subjects.  NeuroD1, Ngn3 and 
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HATH1 protein expression was decreased by 2.5-fold (p = 0.031), 2.7-fold (p = 
0.017) and 1.6-fold (p = 0.014) respectively, in obese compared to lean individuals.  
Conversely, Hes1 protein abundance was 3.4-fold higher (p = 0.001) in the 
duodenum of obese individuals compared to lean controls (Figure 5B-E).  The 
observed change in protein abundance of these transcription factors in obese 
individuals was reversed post-LSG.  The levels of NeuroD1, Ngn3 and HATH1 were 
enhanced 2.9-fold (p = 0.012), 2.3-fold (p = 0.012) and 1.5-fold (p = 0.040), 
respectively, in post-operative obese duodenum.  The increased Hes1 expression 
seen in obese individuals was reduced by 1.9-fold (p = 0.027) post-LSG, equating to 
the level detected in the duodenum of healthy controls (Figure 5B-E). 
 
Discussion 
Gastrointestinal adaptions and alterations in gut hormone secretion levels appear to 
key elements in restoring the metabolic improvements seen after bariatric surgery.  
The two most common and effective procedures are laparoscopic Roux-en-Y gastric 
bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG).  RYGB and LSG 
produce markedly different anatomical rearrangements.  In RYGB a small gastric 
pouch is formed and the duodenum is bypassed, whilst in LSG a larger portion of the 
stomach is resected, but the natural passage is unchanged22.  In spite of these 
fundamental differences, many clinical and metabolic outcomes (e.g. weight loss, 
remission of co-morbidities such as type-2 diabetes) are relatively similar after both 
procedures26,34-36.  Different mechanisms have been proposed for explaining the 
dramatic metabolic improvements.  These include calorie restriction, changes in the 
secretion of incretin, gut hormones and blood glucose levels, accelerated gastric 
emptying and alterations in bile acid signalling.  In RYGB it has been suggested that 
accelerated travel of nutrients to the distal gut may be a mechanism underlying 
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increased secretion of GLP-1 and PYY32.  However this mechanism does not entirely 
explain increased secretion of gut hormones occurring in LSG. 
 
In the present study, we demonstrate a significant increase in EEC numbers after 
LSG.  We show that the decrease in the number of EECs in the obese duodenum is 
also observed in the stomach.  The number of cells expressing ChA, a marker of 
EECs, was significantly reduced (45%) in the intestine of obese individuals compared 
to lean controls.  This profile was also reflected in the number of cells expressing gut 
hormones, both in the stomach (ghrelin) and in the duodenum (CCK, GLP-1, ghrelin 
and PYY).  There were no differences in villus height/crypt-depth in the duodenal 
tissues in obese individuals before and after LSG and to that of control lean subjects, 
indicating that the decline in the number of EECs in obesity is not due to any 
structural changes in the intestinal epithelium.  It was notable, that the population of 
EECs in obese subjects was increased after LSG, almost reaching the cell numbers 
seen in the intestine of lean controls. 
There are a number of recent publications assessing adaptive response of human or 
rat intestine after RYGB or LSG.  It is important to note that in LSG, one can directly 
assess structural and functional changes in the same region of the gut (i.e. 
duodenum) before and after the operation.  However, such comparisons cannot be 
made before and after RYGB, as the duodenum is excluded from nutrient exposure 
and is difficult to access. 
Our study is the first to directly compare structural and functional properties of the 
same region of human intestine (duodenum) before and after LSG surgery.  Our 
results relate to the finding of Cavin et al. (2016) using a “LSG rat model”.  They 
reported that there was no hypertrophy of the jejunal tissue post-surgery, but there 
was an increased number of GLP-1 containing cells35. 
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Alterations in circulating gut hormone levels in obese versus lean subjects have been 
published before.  It has been reported that postprandial release of GLP-1, PYY and 
CCK is attenuated, with ghrelin concentrations also being lower in obese compared 
to lean subjects10.  After both RYGB and LSG, postprandial release of gut hormones 
GLP-1, PYY and CCK is increased10.  The higher number of EECs identified in this 
study may provide an explanation for this increased gut hormone release.   
In LSG, the fundus that contains the majority of ghrelin-releasing cells in the 
stomach, is resected and therefore, patients show permanently attenuated ghrelin 
levels without postprandial decline.  Slightly higher ghrelin levels observed after 12 
months post-operatively compared to 3 months indicate a certain adaption of 
remaining ghrelin releasing cells21. 
Bariatric procedures such as RYGB and LSG are the most effective approaches to 
resolve type-2 diabetes in obese individuals36.  This has stimulated research into the 
role of intestinal glucose absorption in obesity37,38.  The intestinal Na+/glucose 
cotransporter 1, SGLT1, is the major route for the absorption of dietary glucose from 
the lumen of the intestine into absorptive enterocytes15,39-43.  Expression and function 
of SGLT1 is enhanced in the intestine of individuals with type-2 diabetes44 and 
diabetic or obese rodents45,46.  SGLT1 overexpression is associated with profound 
obesity in murine models47 proposing an association between increased intestinal 
glucose transport, diabetes and obesity. 
In this study we show that SGLT1 protein abundance is enhanced in the intestine of 
obese compared to lean controls, and the level is returned to normality after LSG.  
Nguyen et al. 2015, assessing SGLT1 expression at mRNA level, have also reported 
increased mRNA abundance in the duodenum of obese subjects48.  It should be 
borne in mind that assessing expression at both mRNA and protein level will allow 
determining the cellular level of regulation, i.e. transcriptional, post-transcriptional, or 
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translational.  However, it is well-established that the mRNA expression patterns by 
themselves are insufficient for the quantitative description of biological systems49.  
Proteins play major roles in the majority of biological processes and measuring 
protein abundance allows determination of functional relevance. 
We observed that protein expression of the transcription factor Hes1, required for 
absorptive enterocyte differentiation, was increased (compared to lean) in the obese 
intestine, and normalised post-LSG, mirroring changes in SGLT1 protein abundance.   
Our data clearly show that expression levels of the transcription factors HATH1, 
NeuroD1, and Ngn3, necessary for EEC differentiation, were reduced in obese 
intestine, in parallel with the number of EECs.  However, there is no change in the 
number of Paneth cells (defensin-5 positive cells) and there is an overexpression of 
goblet cells (MUC2 labelled cells).  Considering that HATH1 specifies the secretory 
lineage (enteroendocrine, goblet and Paneth cells) our results indicate that there may 
be alterations in further upstream targets of the HATH1 transcription factor cascade 
controlling Paneth and goblet cell differentiation in the obese intestine. 
Luminal and systemic factors have been implicated in controlling intestinal epithelial 
cell differentiation.  There is compelling evidence that intestinal bacteria can regulate 
the expression of epithelial cell differentiation factors such as Hes1, Hath1 and KLF4 
both in vivo and in vitro, and that luminal microbiota can directly affect epithelial cell 
differentiation50. 
Changes in composition and diversity of gut microbiota have been reported in many 
pathological conditions leading to altered microbial-host interactions resulting in host 
malfunctions.  For example, there are significant differences in small bowel microbial 
populations in inflammatory bowel syndrome (IBS) subjects compared to both 
healthy control and non-IBS individuals51.  Reduced gut microbial diversity is also a 
common finding in obesity52 leading to modified microbial-host interactions. 
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With the availability of methodologies to determine changes in mucosa-attached 
microbiota53, one can determine any modifications in duodenal mucosa-attached 
microbiota before and after surgery.  This knowledge will allow a better 
understanding of factors that may be involved in increased secretion of gut hormones 
post-surgery allowing the employment of nutritional and/or therapeutic strategies. 
 
In summary, there is a marked reduction in the number of EECs in the duodenum of 
morbidly obese patients compared to lean controls.  LSG surgery results in an 
increase in the number of EECs to almost normality.  We infer from these data that 
the enhancement in EEC numbers could participate in the markedly increased 
postprandial gut hormone secretion observed after LSG.  Furthermore, the 
decreased EEC numbers in the intestine of morbidly obese individuals mirrors altered 
expression of transcription factors controlling epithelial cell differentiation.  
Deregulation of this regulatory network may lead to defective epithelial differentiation 
resulting in altered functions of the intestinal epithelium. 
Our data support the conclusion that there is a deregulation in intestinal epithelial 
homeostasis in obesity, which is restored by LSG leading to normalisation of 
epithelial cell lineage differentiation. 
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Experimental procedures 
Patient selection criteria and the surgical procedure.  The protocol was approved 
by the State Ethics Committee of Basel, Switzerland (EKBB: 298/12) and conducted 
in accordance with the principles of the Declaration of Helsinki.  Patients recruited 
were those scheduled for bariatric surgery.  All participants gave written informed 
consent.  Exclusion criteria for sleeve gastrectomy patients were: presence of any 
chronic disease of the gastrointestinal tract, and previous gastric surgery.  Exclusion 
criteria for healthy controls were: BMI <18 or >30 kg/m2, any chronic illnesses, 
smoking or substance abuse.  Preoperatively study patients followed the standard 
evaluation for bariatric patients routinely carried out by St. Claraspital and were 
assessed by an interdisciplinary team consisting of a surgeon, endocrinologist, 
nutritionist, and a psychiatrist.  The preoperative assessment included abdominal 
ultrasound, upper gastrointestinal x-ray series, gastroscopy and manometry. 
The same experienced surgeon successfully completed all procedures 
laparoscopically.  The stomach was dissected by a 6-fold linear stapler beginning 2–
4 cm above the pylorus ending at the angle of His over a 35F bougie.  The staple line 
was over-sewn with an absorbable, monofilament running suture and secured by 
Lapra-Ty (Ethicon Endo-Surgery, USA) clips. 
 
Patients, liquid test meal, and plasma removal (Group 1).  Fourteen morbidly 
obese patients (table 1) scheduled for LSG were included in this study.  There were 
no perioperative complications.  For meal studies, subjects were admitted to the 
Phase 1 Research Unit of the University Hospital Basel before and 3 months after 
the operation.  After fasting overnight (at least 10 hours), an antecubital vein catheter 
was inserted and a fasting sample was taken.  Then a liquid test meal with a total 
calorie content of 408 kcal resp. 1708 KJ (Resource diabetes plus 50 g double cream 
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containing 23 g carbohydrates, 15 g proteins and 28 g fat) was served to stimulate 
hormone release.  Blood was drawn at the following times: -15, 0 (corresponding to 
commencing meal intake), 15, 30, 45, 60, 120 and 180 min.  Samples (10 
ml/withdrawal) were collected into EDTA tubes containing aprotinin at a final 
concentration of 500 KIU/ml of blood and a DPP-IV inhibitor; samples were 
immediately processed and kept on ice to avoid peptide breakdown.  After 
centrifugation at 4°C, plasma samples were kept frozen at –20°C until analysis. 
 
Hormone analysis.  The concentrations of cholecystokinin (CCK), glucagon-like-
peptide-1 (GLP-1), PYY and insulin were measured in blood plasma using 
commercially available radioimmunoassay or ELISA kits.  The concentration of 
glucose in the plasma was measured using a commercially available 
glucoseoxidase-method.  For further information please see the supplementary 
methods section.  
 
Gastrointestinal tissue collection (Group 2).  Thirty-three morbidly obese patients 
and 24 lean controls were included in the study.  Three months postoperatively, 27 
out of the 33 obese patients were re-examined (see table 2) and tissue biopsies were 
removed as described in supplementary methods (under gastrointestinal tissue 
collection).  Sample processing and analyses were carried out at the University of 
Liverpool. 
 
Immunohistochemistry.  Tissue biopsies processed into gelatine-embedded blocks 
were sectioned at a thickness of 10μm, and mounted on polysine-coated slides 
(Polysine TM, Germany) in preparation for immunohistochemistry.  For detection of 
chromogranin A, mouse monoclonal anti-chromogranin A (K2H10) antibody (1:300, 
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Abcam, Cambridge, UK) or an affinity-purified goat anti-Chr-A (E-20): sc-18232 
antibody (1:100, Santa Cruz Biotechnology, Santa Cruz, CA) were used.  Ghrelin 
containing cells were identified using an affinity-purified polyclonal rabbit antibody to 
ghrelin (1:100, bs-0467R, Bioss inc, MA, USA).  CCK protein expression was 
detected using an affinity purified goat polyclonal CCK (C-20) antibody (1:200, sc-
21617, Santa Cruz Biotechnology, Santa Cruz, CA).  PYY expressing cells were 
identified using an affinity-purified goat polyclonal peptide YY (N-15) antibody (1:200, 
sc-47318, Santa Cruz Biotechnology, Santa Cruz, CA).  GLP1 and GLP2 containing 
cells were identified by affinity-purified goat polyclonal antibodies, GLP1 (C-17) and 
GLP-2 (C-20) (1:100, sc-7782 & sc- 7781, respectively, Santa Cruz Biotechnology, 
Santa Cruz, CA).  Defensin and mucin 2 were selected as markers of Paneth and 
goblet cells respectively.  Cells expressing defensin and mucin 2 were identified by 
using rabbit monoclonal anti-alpha 5 defensin antibody (EPR14309) (1:3000, Abcam, 
Cambridge, UK) and an affinity-purified rabbit polyclonal anti-Muc2 antibody (1:40, 
Sigma-Aldrich Company Ltd., Dorset, UK).  Secondary antibodies were used as 
appropriate and included FITC-conjugated affinity-purified donkey anti-rabbit and 
anti-mouse IgG and Cy3- conjugated affinity-purified donkey anti-goat IgG (1:500, 
Jackson ImmunoResearch Laboratories, West Grove, PA).  The immunostaining was 
visualized using an epifluorescence microscope (Nikon, UK) and images were 
captured with a Hamamatsu digital camera (C4742-95).  Specificity of 
immunostaining was determined by omitting the primary antibody in control sections 
or by pre-incubating the antibody with an excess of appropriate peptide antigens.  
The quantification of cell numbers in lesser and greater curvature of stomach as well 
as in duodenal biopsies of lean, obese- pre-operative or post-operative patients (for 
ChA, GHR, CCK, PYY, GLP-1, GLP-2 and mucin 2) was performed using a grid 
(500x500 µm²), in a defined field of view as described54, and cells present on a 
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tissue-section of a biopsy within the grid were counted.  This approach prevents bias 
brought by biopsy size.  Between 44-1000 immuno-positive cells were counted 
across 5 sections per patient (3-4 biopsies per patient).  In the case of defensin, 
immuno-positive cell counting was performed on an average of 10 crypts from 3 
different regions of each 3-4 biopsies for each patient. 
 
RNA isolation and quantitative real-time PCR (qPCR).  mRNA abundance was 
determined using cDNA prepared from RNA, isolated from duodenal biopsies.  Real-
time PCR assays were performed using SYBR Green JumpStart Taq ReadyMix for 
QPCR (Sigma Aldrich).  Assays were performed in triplicate using a Rotorgene 3000 
(Qiagen, Crawley, UK) and relative abundance was calculated using RG-3000 
comparative quantification software.  Real-time amplification of RNA polymerase IIA 
(POLR2A) was carried out simultaneously as the control reference (see table S2 for 
qPCR primer sequences). 
 
Cell lysate isolation.  Cell lysates were prepared from two biopsies from the same 
patient using a buffer consisting of 150 mM NaCl, 10 mM Hepes/Tris pH 7.4, 5 mM 
EDTA, 1X complete protease cocktail inhibitor [11836-148-001, Roche Diagnostics 
Ltd, Burgess Hill, UK]).  The cellular homogenate was centrifuged at 500 x g (10 
min).  The final supernatant containing purified cellular lysates was assayed for 
protein concentration (average lysate volume was 62 ± 11 µl with average protein 
concentration being 18.6 ± 2.82 µg/µl).  The purified cellular lysates were mixed with 
sample buffer (62.5 mM Tris/HCl pH 6.8, 10 % [v/v] glycerol, 2 % [w/v] SDS, 0.05 % 
[v/v] β-mercaptoethanol, 0.05 % [w/v] bromophenol blue), in preparation for western 
blotting; with aliquots stored at -20°C until use. 
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Isolation of brush border membrane vesicles.  Brush-border membrane vesicles 
(BBMV) were isolated using Mg2+ precipitation/differential centrifugation as previously 
published39.  The final pellet containing BBMV were re-suspended in an isotonic 
buffer (300 mM mannitol, 20 mM Hepes/Tris pH 7.4, 0.1 mM MgSO4) at a volume of 
10 µl.  In preparation for western blot analysis, aliquots of freshly prepared BBMV 
were assayed for protein content then diluted with sample buffer (see above) and 
stored at -20°C until use. 
 
Western blotting.  For the determination of transcription factor protein abundance, 
protein components of lysates (100 µg) were separated by SDS-polyacrylamide gel 
electrophoresis on 12 % (w/v) polyacrylamide mini gels, containing 0.1 % (w/v) SDS, 
whilst for the determination of SGLT1 protein abundance, protein contents of BBMV 
(20 µg) were separated using 8 % (w/v) polyacrylamide mini gels.  Membranes were 
incubated with either our custom-made antibody to SGLT140,41 or with antibodies to 
Neurogenin3 (ab38548, Abcam, Cambridge, UK), NeuroD1 (ab109224), HATH1 
(ab168374) and Hes1 (ab108937).  Immuno-reactive bands were detected by affinity 
purified horseradish peroxidase-linked anti-rabbit secondary antibody (DAKO Ltd, 
Cambridge, UK) and visualised using Immobilon Western Chemiluminescent HRP 
Substrate (Millipore, Hertfordshire, UK) and Bio-Max Light Chemiluminescence Film 
(Sigma-Aldrich, Poole, Dorset, UK).  The intensity of the immunoreactive bands was 
quantified using scanning densitometry (Total Lab, Newcastle-upon-Tyne, UK).  β-
actin protein abundance was used as a loading control. 
 
Morphometry.  Tissue sections were stained with haematoxylin and eosin solutions 
before dehydration and mounting with D.P.X. neutral mounting medium (Sigma-
Aldrich).  Digital images were captured with an Eclipse E400 microscope and DXM 
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1200 digital camera (Nikon, Kingston upon Thames, Surrey, UK), analysed using 
ImageJ software (Wayne Rasband, US National Institutes of Health, Bethesda, MD) 
and calibrated using a 100 μm gradient slide.  A minimum of three images were 
captured per section with a minimum of 8 sections prepared per individual, with each 
section being 5 sections apart within the block.  All images were captured under the 
same conditions.  The villus height and the crypt depth measurements were 
determined blindly taken from an average of sixteen well oriented crypt-villus units 
per patient. 
 
Statistics.  All parameters were tested for normality by the Shapiro–Wilk test.  
Descriptive statistics were used for demographic variables such as age, weight, 
height, and BMI.  Hormone profiles were calculated using pharmacodynamic 
parameters (area under the concentration–time curve (AUC) and maximum plasma 
concentration (Cmax)).  Pre- and postoperative AUC and Cmax of the hormone 
profiles were compared using Student's paired t-test values.  A one-way ANOVA with 
either a Turkey’s or Holm-Sidak multiple comparison post-test was used to determine 
the significance of  gut hormone, markers of various intestinal epithelial cells and 
transcription factor abundance.  All statistical analyses were carried out using the 
statistical software package SPSS for Windows Version 19.0 (SPSS Inc., Chicago, 
USA) or Graphpad Prism for Windows Version 6.0 (Graphpad Inc., CA, USA).  
Values were reported as mean ± SEM, with p ≤ 0.05 considered as statistically 
significant. 
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Figure and table legends 
Figure 1: Expression of chromogranin, CCK and ghrelin proteins in human 
duodenal biopsies.  Profile of the enteroendocrine cell marker, chromogranin A (A, 
ChA) and the gut hormones CCK (B), ghrelin (C), was determined in the duodenal 
biopsies of lean ( ), obese ( ) and post-operative obese, ( ) by 
immunohistochemistry.  Bar charts (on the right) show number of cells counted 
expressing ChA or gut hormones.  Statistical significance was determined by a One-
way ANOVA with differences between means identified using a Holm-Sidak multiple 
comparison post-test where, *p < 0.05, **p < 0.01 and ***p < 0.001.  Scale bars are 
either 100 or 50 µm. Nuclei are stained blue with 4', 6-diamidino-2-phenylindole 
(Dapi). 
 
Figure 2: Expression profile of chromogranin A mRNA in duodenal biopsies.  
Relative mRNA abundance in lean ( ) and obese ( ) duodenum for ChA 
(enteroendocrine cell marker) determined by qPCR.  Values are means ± SEM, 
normalised to polymerase IIA (POLR2A) RNA expression, n=4.  Statistical 
significance was determined by a Student’s t-test where *p < 0.05. 
 
Figure 3: PYY, GLP-1 and GLP-2 protein expression in human duodenal 
biopsies.  Profile of gut hormones, PYY (A), GLP-1 (B) and GLP-2 (C) was 
determined in the duodenal biopsies of lean ( ), obese ( ) and post-operative 
obese, ( ) by immunohistochemistry.  Bar charts (on the right) show number of cells 
counted expressing the gut hormones.  Statistical significance was determined by a 
One-way ANOVA with differences between means identified using a Holm-Sidak 
multiple comparison post-test test where *p < 0.05, ***p < 0.001.  Scale bars are 
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either 100, 50 or 25 µm. Nuclei are stained blue with 4', 6-diamidino-2-phenylindole 
(Dapi). 
 
Figure 4: Expression profile of defensin5 and mucin-2 in duodenal biopsies.  
(A) Relative mRNA abundance in lean ( ) and obese ( )duodenum for DEFA5 
(Paneth cell marker) and MUC2 (goblet cell marker) determined by qPCR.  Values 
are means ± SEM, normalised to polymerase IIA (POLR2A) RNA expression, n=4.  
(B) profile of defensin 5 (DEFA5; red) and mucin 2 (MUC2; green) determined in lean 
( ), obese ( ) and post-operative obese, ( ) duodenum by immunohistochemistry.  
Bar charts (on the right) show total number of cell counted expressing either DEFA5 
or MUC2.  Statistical significance was determined by a Student’s t-test (A) or One-
way ANOVA with differences between means identified using a Turkey multiple 
comparison post-test (B) where **p < 0.01; ***p < 0.001.  Scale bars are 25 µm. 
Nuclei are stained blue with 4',6-diamidino-2-phenylindole (Dapi). 
 
Figure 5: SGLT1, Hes1, NeuroD1, Ngn3, and HATH1 protein expression 
(western blot) in duodenal biopsies of lean, obese and post-operative.  Protein 
contents of BBMV (20 µg protein), or cell lysates (100 µg protein) separated from 
duodenal biopsies were subjected to western blot analysis using antibodies to 
SGLT1 (A), transcription factors: Hes1 (B), NeuroD1 (C), Ngn3 (D), HATH1 (E) and 
β-actin; the latter was used as a loading control.  Upper panel shows abundance of 
SGLT1, the transcription factor and β-actin proteins determined by western blots and 
lower panel depicts the densitometric analysis of western blots normalising protein 
abundance to that of β–actin: in lean (L) ( ), obese (Ob) ( ) and post-operative 
obese,(POb) ( ) individuals.  Results are shown as mean ± SEM; n=7-10.  
28 
 
Statistically significant results determined using a One-way ANOVA with differences 
between means identified using a Holm-Sidak multiple comparison post-test where 
*P < 0.05 and ***P < 0.001.  For clarity, boxed western blot images are displayed.  
Full length blots are shown in Supplementary Figure S4.  
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Table 1: Baseline demographics and gastrointestinal hormone levels in morbidly 
obese patients (Group 1) pre- and 3 months post-LSG after liquid test meal (408 
kcal) stimulation. 
Parameter Preoperative 
(n= 14) 
3 months 
(n= 14) 
P value  
Gender: male/female 4/10 - - 
Age (years) 37 ± 3 - - 
BMI (kg/m2) 45.5 ± 1.7 39.3 ± 1.4 p ≤ 0.001 
Insulin 
Fasting insulin (µU/ml) 
AUC 0-180 min. 
Cmax (µU/ml) 
 
36.3 ± 6.5 
15,371.5 ± 3,799.0 
152.3 ± 22.7 
 
25.0 ± 3.8 
10,954.3 ± 1,534.4 
182.1 ± 24.9 
 
p = 0.036 
p = 0.297 
p = 0.361 
Glucose 
Fasting glucose (mmol/l) 
AUC 0-180 min. 
Cmax (mmol/l) 
 
6.3 ± 0.5 
1,070.3 ± 64.0 
7.8 ± 0.8 
 
5.3 ± 0.2 
966.7 ± 36.0 
7.4 ± 0.5 
 
p = 0.008 
p = 0.040 
p = 0.493 
HOMA Index 11.2 ± 2.8 6.3 ± 1.3 p = 0.019 
Ghrelin 
Fasting ghrelin (pg/ml) 
AUC 0-180 min. 
Cmax (pg/ml) 
 
504.9 ± 59.6 
89,822.5 ± 9,034.7 
535.6 ± 56.2 
 
272.4 ± 13.9 
50,690.5 ± 2,961.4 
308.2 ± 17.5 
 
p = 0.001 
p = 0.001 
p = 0.001 
CCK 
Fasting CCK (pMol/ml) 
AUC 0-180 min. 
Cmax (pMol/ml) 
 
1.0 ± 0.1 
573.3 ± 73.8 
4.6 ± 0.6 
 
0.8 ± 0.0 
777.1 ± 128.3 
13.6 ± 1.2 
 
p = 0.231 
p = 0.015 
p < 0.001 
GLP-1 
Fasting GLP-1 (pg/ml) 
AUC 0-180 min. 
Cmax (pg/ml) 
 
1.5 ± 0.4 
354.8 ± 62.4 
2.6 ± 0.4 
 
1.1 ± 0.1 
959.4 ± 136.0 
13.4 ± 1.9 
 
p = 0.243 
p = 0.004 
p < 0.001 
PYY 
Fasting PYY (pg/ml) 
AUC 0-180 min. 
Cmax (pg/ml) 
 
113.6 ± 6.9 
23,141.9 ± 1,212.2 
150.5 ± 7.7 
 
95.6 ± 8.6 
43,329.4 ± 7,206.8 
326.8 ± 62.6 
 
p = 0.059 
p = 0.022 
p = 0.019 
Data represent means ± SEM; AUC = area under the concentration time profile; 
Cmax = maximum plasma concentrations.  p-value: pre versus post-surgery, using a 
Student’s paired t-test. 
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Table 2: Baseline demographics in (Group 2) morbidly obese patients pre- and 3 
months post-LSG and lean controls. 
Parameter Lean controls  
(n= 24) 
Obese 
preoperative 
(n= 33) 
Obese  
3 months after 
LSG 
(n= 27) 
P value 
  
Male/female 12/12 14/19 12/15 n.s. 
Age (years) 32.0 ± 2.1 41.2 ± 2.1 41.3 ± 2.2 p = 0.01b 
p = 0.01c 
BMI (kg/m2) 22.8 ± 0.6 47.2 ± 1.7 39.3 ± 1.4 p ≤ 0.001a 
p ≤ 0.001b 
p ≤ 0.001c 
Data represent means ± SEM; p-value: apre versus post-surgery, bnon-operated 
obese vs. lean, cobese post-surgery vs. lean, using a Student’s paired t-test. 





